Preliminary study of T 705 shows efficacy in COVID-19 with data is published in The Lancet.- Fujifilm

The Lancet has published a preliminary study report on Turkey's using T 705 (favipiravir), from Fujifilm, produced by Hisun, to treat COVID-19. The report says after favipiravir was used in hospitals across Turkey for five days, the percentage of patients requiring ICU admission diminished from 24% to 12%, whilst the percentage intubated fell from 77% to 66%. These differences were both statistically significant. It concludes that the addition of favipiravir to the national COVID-19 treatment protocol may explain this rapid decrease in the rate of ICU admissions and intubation. See: "ICU Admission Rates in Istanbul Following the Addition of Favipiravir to the National COVID-19 Treatment Protocol" Abdullah Emre Güner et al. The Lancet 27 July 2020 http://dx.doi.org/10.2139/ssrn.3622357